Heron Therapeutics Inc. | Micro-cap | Healthcare
$1.35
-2.88%
| Heron Therapeutics Stock Comparison:
Heron Therapeutics vs VertexHeron Therapeutics vs RegeneronHeron Therapeutics vs Editas MedicineHeron Therapeutics vs Silence TherapeuticsHeron Therapeutics vs AlectorHeron Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 37.2M
Gross Profit 27.3M 73.50%
Operating Income -1.6M -4.40%
Net Income -2.4M -6.40%
EPS (Diluted) $-0.02

Balance Sheet Metrics

Total Assets 235.8M
Total Liabilities 264.2M
Shareholders Equity -28.5M

Cash Flow Metrics

Operating Cash Flow 2.9M
Free Cash Flow -9.0M

Revenue & Profitability Trend

Heron Therapeutics Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i144.3M127.0M107.7M86.3M88.6M
Cost of Goods Sold i38.6M65.1M54.9M46.0M36.2M
Gross Profit i105.6M61.9M52.8M40.3M52.4M
Gross Margin % i73.2%48.8%49.0%46.7%59.2%
Operating Expenses
Research & Development i16.7M55.9M107.5M130.8M174.5M
Selling, General & Administrative i100.5M116.7M120.0M127.3M106.1M
Other Operating Expenses i-----
Total Operating Expenses i117.2M172.6M227.5M258.2M280.6M
Operating Income i-11.5M-110.6M-174.7M-217.8M-228.2M
Operating Margin % i-8.0%-87.1%-162.2%-252.3%-257.4%
Non-Operating Items
Interest Income i3.6M3.4M1.6M433.0K3.6M
Interest Expense i6.0M3.9M2.5M2.4M1.9M
Other Non-Operating Income430.0K560.0K-6.5M-878.0K-847.0K
Pre-tax Income i-13.6M-110.6M-182.0M-220.7M-227.3M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-13.6M-110.6M-182.0M-220.7M-227.3M
Net Margin % i-9.4%-87.0%-169.1%-255.6%-256.4%
Key Metrics
EBITDA i-5.1M-103.8M-176.7M-215.3M-222.5M
EPS (Basic) i$-0.09$-0.80$-1.67$-2.24$-2.50
EPS (Diluted) i$-0.09$-0.80$-1.67$-2.24$-2.50
Basic Shares Outstanding i1524490001381350001089964079847100090774000
Diluted Shares Outstanding i1524490001381350001089964079847100090774000

Income Statement Trend

Heron Therapeutics Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i25.8M28.7M15.4M90.5M105.1M
Short-term Investments i33.5M51.7M69.5M67.0M103.4M
Accounts Receivable i78.9M60.1M52.0M35.5M41.8M
Inventory i53.2M42.1M54.6M48.4M41.9M
Other Current Assets17.7M6.1M14.0M13.0M22.0M
Total Current Assets i209.0M188.8M205.4M254.4M314.2M
Non-Current Assets
Property, Plant & Equipment i33.1M39.5M41.0M43.2M45.4M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets6.5M8.1M15.7M17.7M346.0K
Total Non-Current Assets i24.1M33.7M45.5M51.3M39.4M
Total Assets i233.1M222.5M251.0M305.7M353.6M
Liabilities
Current Liabilities
Accounts Payable i11.7M3.8M3.6M3.9M629.0K
Short-term Debt i3.0M3.1M2.7M2.4M10.0M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i91.5M79.7M82.4M71.1M102.5M
Non-Current Liabilities
Long-term Debt i174.7M176.6M154.8M157.1M14.6M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities615.0K241.0K241.0K--
Total Non-Current Liabilities i175.3M176.8M155.0M157.1M14.6M
Total Liabilities i266.8M256.5M237.4M228.1M117.1M
Equity
Common Stock i1.5M1.5M1.2M1.0M913.0K
Retained Earnings i-1.9B-1.9B-1.8B-1.6B-1.4B
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-33.7M-34.0M13.6M77.6M236.5M
Key Metrics
Total Debt i177.8M179.6M157.5M159.5M24.6M
Working Capital i117.6M109.1M123.1M183.4M211.7M

Balance Sheet Composition

Heron Therapeutics Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-13.6M-110.6M-182.0M-220.7M-227.3M
Depreciation & Amortization i2.5M2.9M2.9M3.0M2.8M
Stock-Based Compensation i13.0M32.9M43.0M46.9M50.2M
Working Capital Changes i-21.3M4.4M-23.3M3.2M-21.1M
Operating Cash Flow i-18.5M-70.1M-159.3M-166.8M-193.9M
Investing Activities
Capital Expenditures i-1.7M-1.5M-1.6M-3.0M-6.8M
Acquisitions i-----
Investment Purchases i-103.1M-87.7M-145.7M-129.2M-134.0M
Investment Sales i123.5M107.2M144.0M164.9M349.8M
Investing Cash Flow i18.7M18.0M-3.3M32.7M209.0M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i024.4M0149.0M26.0K
Debt Repayment i----0
Financing Cash Flow i054.1M75.1M149.0M26.0K
Free Cash Flow i-24.2M-60.3M-148.7M-206.4M-191.6M
Net Change in Cash i224.0K2.0M-87.5M14.9M15.1M

Cash Flow Trend

Heron Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -15.44
Forward P/E 178.00
Price to Book -7.85
Price to Sales 1.42
PEG Ratio 0.23

Profitability Ratios

Profit Margin -0.62%
Operating Margin -4.40%
Return on Equity 40.36%
Return on Assets 0.34%

Financial Health

Current Ratio 0.82
Debt to Equity -6.48
Beta 1.16

Per Share Data

EPS (TTM) $-0.01
Book Value per Share $-0.18
Revenue per Share $0.98

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
hrtx212.3M-15.44-7.8540.36%-0.62%-6.48
Vertex 99.5B27.635.7922.77%31.86%8.89
Regeneron 62.2B14.802.0415.34%31.37%9.04
Editas Medicine 231.1M-0.8911.68-188.58%0.00%110.14
Silence Therapeutics 244.2M-5.152.59-66.96%-291.24%0.00
Alector 237.8M-1.913.34-103.99%-142.10%55.47

Financial data is updated regularly. All figures are in the company's reporting currency.